Key insights
- Bristol Myers Squibb is partnering with Anthropic to deploy its Claude AI model, aiming to accelerate drug discovery and development. This move, along with Eli Lilly's partnership with Nvidia, signals a growing trend of AI adoption in the pharmaceutical industry. McKinsey estimates Agentic AI could boost clinical development productivity by 35-45% in the next five years, suggesting a positive outlook for the sector's efficiency and innovation.
May 20 (Reuters) - Bristol Myers Squibb said on Wednesday it is partnering with Anthropic to make its Claude AI model available to over 30,000 employees in an effort to accelerate the discovery, development and delivery of new medicines.
-
Bristol said it will also leverage Claude Code, Anthropic's coding tool, and evaluate its use in research, drug development, manufacturing and other commercial and medical affairs.
-
Drugmakers have announced a slew of deals for tools to unleash the promise of artificial intelligence.
-
Many, including drugmaker Eli Lilly, which has partnered with leading chipmaker Nvidia, are betting AI can also improve the success rate of new drugs.
-
"Most enterprise AI stops at the chatbot. The real prize is the untapped value still trapped behind decades of data silos, and this collaboration is how we reach it," said Greg Meyers, chief digital and technology officer at Bristol Myers.
-
Agentic AI, which requires little human intervention, could increase clinical development productivity by about 35% to 45% over the next five years, consultancy McKinsey said last year.
(Reporting by Christy Santhosh in Bengaluru; Editing by Sahal Muhammed)